A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

This study is testing whether adding a GLP-1 agonist (a hormone-based medication similar to drugs like semaglutide, often used for diabetes and weight loss) to a hormonal IUD (levonorgestrel) can help treat early-stage uterine cancer or pre-cancerous uterine changes in obese women who want to avoid surgery. **You may be eligible if:** - You are 18 or older - You have been diagnosed in the last 3 months with grade 1 endometrial (uterine) adenocarcinoma or pre-cancerous uterine changes (endometrial intraepithelial neoplasia) - Your cancer has not spread beyond the uterus (confirmed by MRI or ultrasound) - Your BMI is 30 or higher - You have obesity-related health conditions such as high blood pressure, diabetes, or sleep apnea **You may NOT be eligible if:** - Your cancer has spread outside the uterus or into the uterine muscle - You are not obese (BMI under 30) - You have conditions that make this treatment unsafe (e.g., history of pancreatitis) Talk to your doctor to see if this trial is right for you.